This article was originally published in The Gray Sheet
Registration statement filed with the Securities and Exchange Commission and effective June 30 covers 2.6 mil. shares of common stock and 1 mil. Class A warrants being offered by selling shareholders and warrant holders. Although no proceeds from the sale will go to the company, the firm could receive "up to" about $4.3 mil. if the warrants are exercised "and all other outstanding options and warrants for which the underlying shares of common stock have been registered are exercised by the holders thereof." The warrants are listed under the symbol "LAZRW" on the NASDAQ exchange, entitle the holder to purchase one share of common stock at an exercise price of $3.25, and expire on Sept. 30, 1995....
You may also be interested in...
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.